Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

John J. Nemunaitis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2234-2381; OpenAlex author ID A5055054082. Sources: ClinicalTrials.gov.

Their work

Papers
14 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: 1 paper · 2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 14

  1. Smart exosomes enhance PDAC targeted therapy. Co-author DOI 10.1016/j.jconrel.2024.02.037↗
  2. Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2020.08.002↗
  3. A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1634/theoncologist.2020-0321↗
  4. BIRC5 is a target for molecular imaging and detection of human pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.04.036↗
  5. A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.01.007↗
  6. KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. Last author DOI 10.1371/journal.pone.0193644↗
  7. Pancreatic cancer actionable genes in precision medicine and personalized surgery. Co-author DOI 10.1016/j.surge.2016.05.002↗
  8. Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2174/1566524016666151222145551↗
  9. Liposomal insulin promoter-thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice. Co-author DOI 10.1016/j.canlet.2015.01.002↗
  10. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Ther… Co-author DOI 10.1200/jco.2015.61.4578↗
  11. Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform. Co-author DOI 10.1038/cgt.2013.84↗
  12. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer… Co-author DOI 10.1016/j.gie.2011.10.007↗
  13. PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. Co-author DOI 10.1371/journal.pone.0040452↗
  14. PDX-1: demonstration of oncogenic properties in pancreatic cancer. Co-author DOI 10.1002/cncr.25629↗

Trials 1

  1. Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies Principal investigator NCT01041235↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Francis Charles Brunicardi · 11 shared papers, 2011–2024 · strength 0.86
  2. Shi‐He Liu · 7 shared papers, 2011–2024 · strength 0.60
  3. Justin F. Creeden · 3 shared papers, 2019–2024 · strength 0.39
  4. Donald Rao · 4 shared papers, 2012–2024 · strength 0.35
  5. Juehua Yu · 3 shared papers, 2017–2020 · strength 0.27
  6. Jingyuan Liu · 1 shared paper, 2024 · strength 0.20
  7. James X. Wu · 3 shared papers, 2014–2016 · strength 0.16
  8. Guisheng Zhou · 4 shared papers, 2011–2016 · strength 0.14
  9. Enrique Rozengurt · 2 shared papers, 2016–2017 · strength 0.14
  10. Nishanthan Rajakumaraswamy · 1 shared paper, 2020 · strength 0.13
  11. Michael Jon Pishvaian · 1 shared paper, 2020 · strength 0.13
  12. Erkut Hasan Borazanci · 1 shared paper, 2020 · strength 0.13
  13. Colin D. Weekes · 1 shared paper, 2020 · strength 0.13
  14. Jeffrey M. Sutton · 1 shared paper, 2020 · strength 0.10
  15. James W. Sinnett‐Smith · 1 shared paper, 2016 · strength 0.05
  16. Marie‐Claude Gingras · 2 shared papers, 2011–2012 · strength 0.05
  17. Jon M Rogers · 1 shared trial, 2009 · strength 0.05
  18. Anthony W Tolcher · 1 shared trial, 2009 · strength 0.05
  19. Zev A. Wainberg · 1 shared paper, 2015 · strength 0.04
  20. Herbert I. Hurwitz · 1 shared paper, 2015 · strength 0.04
  21. Richard S. Levy · 1 shared paper, 2015 · strength 0.04
  22. Johanna C. Bendell · 1 shared paper, 2015 · strength 0.04
  23. J. Marc Pipas · 1 shared paper, 2015 · strength 0.04
  24. Min Li · 1 shared paper, 2011 · strength 0.03
  25. Changyi Chen · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.